Metabolic syndrome and C-reactive protein concentration as independent correlates of chronic kidney disease

References

• El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331–40
   PubMed Web of Science ®Google Scholar
• Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004;291:844–50
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5
   PubMed Web of Science ®Google Scholar
• Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011;6:364–73
   Google Scholar
• Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97 (Suppl.):3A–11A
   Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115–26
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391–7
   PubMed Web of Science ®Google Scholar
• Rutter MK, Meigs JB, Sullivan LM, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380–5
   PubMed Web of Science ®Google Scholar
• Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31:S29–34
   Google Scholar
• Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007;49:46–55
   PubMed Web of Science ®Google Scholar
• Yang T, Chu CH, Bai CH, et al. Uric acid level as a risk marker for metabolic syndrome: a Chiinese cohort study. Atherosclerosis 2012;220:525–31
   PubMed Web of Science ®Google Scholar
• Topouchian JA, El Assaad MA, Orobinskaia LV, et al. Validation of two devices for self-measurement of brachial blood pressure according to the International Protocol of the European Society of Hypertension: the SEINEX SE-9400 and the Microlife BP 3AC1-1. Blood Press Monit 2005;10:325–31
   PubMed Web of Science ®Google Scholar
• Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications, part 2. Clin Chem 2001;47:418–25
   PubMed Web of Science ®Google Scholar
• National Kidney Fundation. K/DOQ1 clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:s1–266
   Google Scholar
• Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499–511
   PubMed Web of Science ®Google Scholar
• Chien KL, Lin HJ, Lee BC, et al. A prediction model for the risk of incident chronic kidney disease. Am J Med 2010;123:836–46
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med 1997;337:396–407
   PubMed Web of Science ®Google Scholar
• Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498–509
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173:309–14
   PubMed Web of Science ®Google Scholar
• Thomas GN, Schooling CM, McGhee SM, et al. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol 2007;66:666–71
   PubMed Web of Science ®Google Scholar
• Panichi V, Migliori M, De PS, et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002;91:594–600
   PubMed Web of Science ®Google Scholar
• Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is a ssociated with renal function abnormalities in a non-diabetic population. Kidney Int 2003;63:654–61
   PubMed Web of Science ®Google Scholar
• Fox ER, Benjamin EJ, Sarpong DF, et al. The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol 2010;11:1–7
   PubMed Web of Science ®Google Scholar
• Westhuyzen J, Healy H. Review: biology and relevance of C-reactive protein in cardiovascular and renal disease. Ann Clin Lab Sci 2000;30:133–43
   PubMed Web of Science ®Google Scholar
• Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59:407–14
   PubMed Web of Science ®Google Scholar
• Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 2011;80:1231–8
   Google Scholar
• Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West Scotland Coronary Prevention Study. Circulation 2003;108:414–9
   PubMed Web of Science ®Google Scholar
• Beddhu S, Kimmel PL, Ramkumar N, Cheung AK. Associations of metabolic syndrome with inflammation in CKD: results from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2005;46:577–86
   PubMed Web of Science ®Google Scholar
• Chen PC, Chien KL, Hsu HC, et al. Metabolic syndrome and C-reactive protein in stroke prediction: a prospective study in Taiwan. Metabolism 2009;58:772–8
   PubMed Web of Science ®Google Scholar
• Lee JE, Choi SY, Huh W, et al. Metabolic syndrome, C-reactive protein, and chronic kidney disease in nondiabetic, nonhypertensive adults. Am J Hyperten 2007;20:1189–94
   PubMedGoogle Scholar
• Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444–50
   PubMed Web of Science ®Google Scholar
• Meier-Ewert HKM, Ridker PM, Rifai N, et al. Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem 2001;47:426–30
   PubMed Web of Science ®Google Scholar
• Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005;45:463–72
   PubMed Web of Science ®Google Scholar
• Wen CP, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008;371:2173–82
   PubMed Web of Science ®Google Scholar
• Cheng TYD, Wen SF, Astor BC, et al. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am J Kidney Dis 2008;52:1051–60
   PubMed Web of Science ®Google Scholar